Dendritic cell-based immunotherapy in ovarian cancer

Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise....

Descripción completa

Detalles Bibliográficos
Autores principales: Coosemans, An, Vergote, Ignace, Van Gool, Stefaan W
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2013
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913669/
https://www.ncbi.nlm.nih.gov/pubmed/24501688
http://dx.doi.org/10.4161/onci.27059
_version_ 1782302267764899840
author Coosemans, An
Vergote, Ignace
Van Gool, Stefaan W
author_facet Coosemans, An
Vergote, Ignace
Van Gool, Stefaan W
author_sort Coosemans, An
collection PubMed
description Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise. Here, we present our view on an optimal dendritic cell-based immunotherapeutic strategy against ovarian cancer.
format Online
Article
Text
id pubmed-3913669
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-39136692014-02-05 Dendritic cell-based immunotherapy in ovarian cancer Coosemans, An Vergote, Ignace Van Gool, Stefaan W Oncoimmunology Author's View Worldwide, 80% of patients with ovarian cancer die of the disease. New treatments for this aggressive disease are therefore being intensively searched. Although dendritic cell-based vaccines against gynecological malignancies are in their infancy, this immunotherapeutic approach holds much promise. Here, we present our view on an optimal dendritic cell-based immunotherapeutic strategy against ovarian cancer. Landes Bioscience 2013-12-01 2013-11-06 /pmc/articles/PMC3913669/ /pubmed/24501688 http://dx.doi.org/10.4161/onci.27059 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Coosemans, An
Vergote, Ignace
Van Gool, Stefaan W
Dendritic cell-based immunotherapy in ovarian cancer
title Dendritic cell-based immunotherapy in ovarian cancer
title_full Dendritic cell-based immunotherapy in ovarian cancer
title_fullStr Dendritic cell-based immunotherapy in ovarian cancer
title_full_unstemmed Dendritic cell-based immunotherapy in ovarian cancer
title_short Dendritic cell-based immunotherapy in ovarian cancer
title_sort dendritic cell-based immunotherapy in ovarian cancer
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3913669/
https://www.ncbi.nlm.nih.gov/pubmed/24501688
http://dx.doi.org/10.4161/onci.27059
work_keys_str_mv AT coosemansan dendriticcellbasedimmunotherapyinovariancancer
AT vergoteignace dendriticcellbasedimmunotherapyinovariancancer
AT vangoolstefaanw dendriticcellbasedimmunotherapyinovariancancer

Ejemplares similares